<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625064</url>
  </required_header>
  <id_info>
    <org_study_id>20151030</org_study_id>
    <nct_id>NCT02625064</nct_id>
  </id_info>
  <brief_title>Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome</brief_title>
  <acronym>ARDS</acronym>
  <official_title>Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to find a series novel biomarkers by differential proteomic
      techniques that can improve the early diagnosis and develop a more efficient therapy to
      enhance ARDS patient survival rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory distress syndrome(ARDS) has a very poor prognosis and high mortality. To
      improve the early diagnosis of ARDS, there is an urgent need for novel biomarkers of ARDS.
      The goal of this project is to find a series novel biomarkers by differential proteomic
      techniques that can improve the early diagnosis and develop a more efficient therapy to
      enhance ARDS patient survival rate. Clinical data and blood sample were recorded before
      treatment and after treatment. Acute Physiology And Chronic Health Evaluation III (APACHE
      III) scores were calculated at enrolment. Studying blood specimens from different period ARDS
      patients by proteomic analysis. It can provide information on a complex composition of
      proteins that are differentially expressed, which could be used for discovering high
      sensitivity and specificity ARDS biomarker.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of serum proteins directly by proteomics analysis to identify new biomarkers of ARDS</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of serum proteins directly by proteomics analysis to identify new biomarkers of ARDS</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>APACHE III score</measure>
    <time_frame>baseline, 1week, 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>baseline, day 3, day 5, 1week, 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality or multi-organ failure</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>1: patient at High risk for ARDSp</arm_group_label>
    <description>Severe pneumonia and（PaO2/FIO2）＞300mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: patient at High risk for ARDSexp</arm_group_label>
    <description>Severe sepsis and without ARDS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: mild ARDS</arm_group_label>
    <description>PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: moderate ARDS</arm_group_label>
    <description>PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: severe ARDS</arm_group_label>
    <description>PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples collection before treatment</intervention_name>
    <arm_group_label>1: patient at High risk for ARDSp</arm_group_label>
    <arm_group_label>2: patient at High risk for ARDSexp</arm_group_label>
    <arm_group_label>3: mild ARDS</arm_group_label>
    <arm_group_label>4: moderate ARDS</arm_group_label>
    <arm_group_label>5: severe ARDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples collection after treatment</intervention_name>
    <arm_group_label>1: patient at High risk for ARDSp</arm_group_label>
    <arm_group_label>2: patient at High risk for ARDSexp</arm_group_label>
    <arm_group_label>3: mild ARDS</arm_group_label>
    <arm_group_label>4: moderate ARDS</arm_group_label>
    <arm_group_label>5: severe ARDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker proteomic analysis</intervention_name>
    <arm_group_label>1: patient at High risk for ARDSp</arm_group_label>
    <arm_group_label>2: patient at High risk for ARDSexp</arm_group_label>
    <arm_group_label>3: mild ARDS</arm_group_label>
    <arm_group_label>4: moderate ARDS</arm_group_label>
    <arm_group_label>5: severe ARDS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients at High risk for Extra-pulmonary ARDS and pulmonary ARDS; patients who have ARDS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The Berlin definition of acute respiratory distress syndrome

          -  ATS definition of severe pneumonia

        Exclusion Criteria:

          -  age below 18 years

          -  pregnancy

          -  Expected survival under 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pinhua Pan, MD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pinhua Pan, MD, Doctor</last_name>
    <phone>+86 13574810968</phone>
    <email>pinhuapan668@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pinhua Pan, MD，Doctor</last_name>
      <phone>+8613574810968</phone>
      <email>pinhuapan668@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Janz DR, Ware LB. Biomarkers of ALI/ARDS: pathogenesis, discovery, and relevance to clinical trials. Semin Respir Crit Care Med. 2013 Aug;34(4):537-48. doi: 10.1055/s-0033-1351124. Epub 2013 Aug 11. Review.</citation>
    <PMID>23934723</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Calfee CS. Biomarkers of ARDS: what's new? Intensive Care Med. 2016 May;42(5):797-799. doi: 10.1007/s00134-015-3973-0. Epub 2015 Jul 15.</citation>
    <PMID>26174184</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA; NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010 Feb;137(2):288-96. doi: 10.1378/chest.09-1484. Epub 2009 Oct 26.</citation>
    <PMID>19858233</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>December 5, 2015</last_update_submitted>
  <last_update_submitted_qc>December 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>biomarkers</keyword>
  <keyword>proteomic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

